Missouri Medicaid spending on GLP-1 drugs

How much did Missouri Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $284.9 million for GLP-1 drugs paid through Missouri Medicaid in 2025, across at least 285,105 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 47 rows of 165, so these figures are floors.

Pharmacies were reimbursed at least $121.2 million for GLP-1 drugs paid through Missouri Medicaid in 2026 (quarter 1 only, as posted so far), across at least 116,884 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 10 rows of 38, so these figures are floors.

By year and ingredient

2020at least $848,188No data$12,712,058at least $1,116,005at least $5,480,826$24,354at least $10,846at least $20,192,278
2021at least $1,560,821No data$18,999,669at least $2,377,509at least $3,814,477at least $34,126Suppressedat least $26,786,601
2022at least $2,107,163at least $37,838$21,064,169at least $27,985,304at least $1,251,893$40,454Suppressedat least $52,486,821
2023at least $4,601,255at least $787,776$22,194,904at least $76,430,062$1,512,146at least $25,867Suppressedat least $105,552,010
2024at least $7,288,364$1,834,873at least $12,385,558at least $91,688,629$3,195,654at least $6,889Suppressedat least $116,399,966
2025at least $73,684,362$134,043,434at least $1,831,057at least $74,680,574at least $623,769SuppressedSuppressedat least $284,863,196
2026 (Q1)at least $25,390,864$83,266,962at least $201,966at least $12,345,513No dataNo dataSuppressedat least $121,205,304

By product, 2025

Ozempicat least $73,283,867at least 75,1704 of 16
Rybelsusat least $117,709at least 1568 of 17
Wegovyat least $282,786at least 4852 of 20
Mounjaro$1,253,2362,3350 of 24
Zepbound$132,790,198125,3870 of 24
Liraglutide (generic name listing)at least $6,462at least 1918 of 19
Victoza$1,824,5942,7350 of 8
Trulicityat least $74,680,574at least 78,0644 of 20
Bydureon$47,696590 of 2
Byettaat least $576,073at least 6952 of 6
Exenatide (generic name listing)SuppressedSuppressed2 of 2
SoliquaSuppressedSuppressed3 of 3
XultophySuppressedSuppressed4 of 4

By quarter, 2025

Q1 2025at least $38,105,481at least 40,53510 of 40
Q2 2025at least $56,209,205at least 56,94313 of 44
Q3 2025at least $88,324,301at least 87,40814 of 42
Q4 2025at least $102,224,209at least 100,21910 of 39

By quarter, 2026 (posted so far)

Q1 2026at least $121,205,304at least 116,88410 of 38

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.